<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1607">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04348461</url>
  </required_header>
  <id_info>
    <org_study_id>BALMYS-19</org_study_id>
    <nct_id>NCT04348461</nct_id>
  </id_info>
  <brief_title>BAttLe Against COVID-19 Using MesenchYmal Stromal Cells</brief_title>
  <official_title>Two-treatment,Randomized, Controlled, Multicenter Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Expanded Allogeneic Adipose Tissue Adult Mesenchymal Stromal Cells in Critically Ill Patients COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Investigación Sanitaria y Biomédica de Alicante</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital General Universitario Gregorio Marañon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinica Universidad de Navarra, Universidad de Navarra</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario de Salamanca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital General Universitario de Alicante</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Clínico Universitario Virgen de la Arrixaca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigational medicinal product consists of expanded allogeneic mesenchymal stromal
      cells derived from adipose tissue and administered intravenously.

      The objective of this project is to evaluate the safety and efficacy of the administration of
      expanded allogeneic adipose tissue adult mesenchymal stem cells, in patients infected with
      SARS-COV-2 with COVID-19 type complications.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 6, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Survival Rate)</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Adverse Event Rate</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COVID</condition>
  <condition>Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients receiving regular respiratory distress treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving two serial doses of allogeneic and expanded adipose tissue-derived mesenchymal stromal cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells</intervention_name>
    <description>Two serial doses of 1.5 million adipose-tissue derived mesenchymal stem cells per kg</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of both sexes.

          -  Over 18 years.

          -  Confirmation of SARS-COV-2 infection by RT-PCR in respiratory sample.

          -  Respiratory failure requiring intubation and connection to mechanical ventilation,
             secondary to SARS-CoV-2 infection.

          -  Criteria for acute respiratory distress: acute bilateral alveolar-interstitial
             infiltrate not compatible with left ventricular failure (demonstrated with ultrasound
             or hemodynamic parameters), sudden onset, and blood gas compromise with a PaO2 / FiO2
             ratio &lt;200 mm-Hg.

          -  Women of childbearing potential should have a negative urine pregnancy test performed
             at the time of study enrollment.

          -  Written or verbal informed consent from the patient, family member or legal
             representative.

        Exclusion Criteria:

          -  Any other cause of acute respiratory distress not attributable to SARS-Cov-2.

          -  RT-PCR of SARS-Cov-2 negative.

          -  Multi-organ failure (more than three organs)

          -  Severe respiratory failure requiring extracorporeal support (ECMO) Grave Moderate
             severe COPD requiring chronic home oxygen therapy, need for prior home oxygen therapy
             for any reason.

          -  Pregnancy, lactation and women of childbearing age but who do not take effective
             contraceptive measures.

          -  Active tumor disease.

          -  Previous immunosuppressive treatment.

          -  Allergy or hypersensitivity to the administered products.

          -  History of deep vein thrombosis or pulmonary embolism in the last 3 years.

          -  Participation in other clinical trials during the 3 months prior to the initial visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Barbara Juan, MD</last_name>
    <phone>0034 915 50 48 00</phone>
    <phone_ext>2431</phone_ext>
    <email>barbara.soria@quironsalud.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mireia Arcas</last_name>
    <phone>0034 915 50 48 00</phone>
    <email>mireia.arcas@fjd.es</email>
  </overall_contact_backup>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 10, 2020</study_first_submitted>
  <study_first_submitted_qc>April 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2020</study_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

